solid tumor
Conditions
Interventions
Experimental group:mecapegfilgrastim injection
Sponsors
The Second Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. Patients with histologically and/or cytologically confirmed esophageal, lung, and female tumors (cervical and endometrial cancers); 3. ECOG score 0-2; 4. Normal function of major organs; 5. Patients can tolerate concurrent chemoradiotherapy with indications; 6. Volunteer to participate in the clinical trial, understand the study procedure and sign the informed consent in person.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients; 2. Previous bone marrow transplantation and/or stem cell transplantation; 3. Other hematological diseases affecting the hematopoietic function of bone marrow; 4. Allergic to study drugs or other G-CSF products or biological agents expressed by Escherichia coli; 5. Patients with acute infection or active infection, or received systemic anti-infective therapy within 72 hours before chemotherapy; 6. Those who had received clinical trials of other drugs within 1 month before enrollment; 7. Concomitant diseases that, in the judgment of the investigator, seriously endanger the safety of patients or affect the completion of the study; 8. Other circumstances that are not suitable for inclusion in this study as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 3/4 neutropenia during concurrent chemoradiotherapy; | — |
Countries
China
Contacts
Public ContactSong Xiang
The Second Affiliated Hospital of Shanxi Medical University
Outcome results
None listed